Clinical Trial Update: Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

A Phase 2 induction and maintenance trial evaluating BMS-936557 for moderate-to-severe ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• BMS-936557

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Colitis, Ulcerative | Phase 2 | Status: COMPLETED